Streptococcus pseudopneumoniae, an opportunistic pathogen in patients with cystic fibrosis

被引:13
|
作者
Dupont, Chloe [1 ]
Michon, Anne-Laure [2 ]
Normandin, Marion [3 ]
Salom, Guillaume [3 ]
Latypov, Marie [4 ]
Chiron, Raphael [5 ]
Marchandin, Helene [6 ]
机构
[1] Univ Montpellier, HydroSci Montpellier, Lab Ecol Microbienne Hosp, Montpellier Univ Hosp,IRD,CNRS, Montpellier, France
[2] Montpellier Univ Hosp, Lab Bacteriol, Montpellier, France
[3] Univ Montpellier, CNRS, HydroSci Montpellier, IRD, Montpellier, France
[4] Montpellier Univ Hosp, Ctr Ressources & Competences Mucoviscidose, Montpellier, France
[5] Univ Montpellier, HydroSci Montpellier, Ctr Ressources & Competences Mucoviscidose, Montpellier Univ Hosp,CNRS,IRD, Montpellier, France
[6] Univ Montpellier, Nimes Univ Hosp, Dept Microbiol, HydroSci Montpellier,CNRS,IRD, Nimes, France
关键词
Cystic fibrosis; Streptococcus pseudopneumoniae; Opportunistic pathogen; Exacerbation; Identification; Resistance; PNEUMONIAE; RESISTANCE;
D O I
10.1016/j.jcf.2019.11.004
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The pathogenic power of Streptococcus pseudopneumoniae has been specified over years, particularly in case of chronic respiratory diseases; S. pseudopneumoniae isolation has however not been characterized before in CF patients. Identification of S. pseudopneumoniae remains challenging due to the high similarity level between species of the Streptococcus mitis group. Twenty CF patients with S. pseudopneumoniae were included. Isolates initially identified by phenotypic routine methods were subjected to both recA sequencing and amplification of S. pseudopneumoniae specific markers. Microbiological and clinical data were reviewed for patients with confirmed S. pseudopneumoniae. Thirteen isolates actually belong to S. pseudopneumoniae. S. pseudopneumoniae was associated with pulmonary exacerbation in 46% of the patients, either as the sole pathogen or as part of a polymicrobial infectious process. S. pseudopneumoniae has to be considered as an additional opportunistic pathogen in CF and additional studies are needed to increase knowledge of its epidemiology and clinical significance in CF. (C) 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:E28 / E31
页数:4
相关论文
共 50 条
  • [21] Manganese Depletion Leads to Multisystem Changes in the Transcriptome of the Opportunistic Pathogen Streptococcus sanguinis
    Puccio, Tanya
    Kunka, Karina S.
    Zhu, Bin
    Xu, Ping
    Kitten, Todd
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [22] Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen
    Hansen, Christine R.
    CURRENT OPINION IN PULMONARY MEDICINE, 2012, 18 (06) : 628 - 631
  • [23] Development of a real-time PCR assay for the specific detection and identification of Streptococcus pseudopneumoniae using the recA gene
    Sistek, V.
    Boissinot, M.
    Boudreau, D. K.
    Huletsky, A.
    Picard, F. J.
    Bergeron, M. G.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (11) : 1089 - 1096
  • [24] Septicemia with Streptococcus pseudopneumoniae: report of three cases with an apparent hepatic or bile duct association
    Fuursted, Kurt
    Littauer, Pia Jeanette
    Greve, Thomas
    Scholz, Christian F. P.
    INFECTIOUS DISEASES, 2016, 48 (08) : 636 - 639
  • [25] The Airway Colonization by Opportunistic Filamentous Fungi in Patients with Cystic Fibrosis: Recent Updates
    Touati K.
    Nguyen D.N.L.
    Delhaes L.
    Current Fungal Infection Reports, 2014, 8 (4) : 302 - 311
  • [26] Group B streptococcus (GBS) is an important pathogen in human disease-but what about in cystic fibrosis?
    Skolnik, Kate
    Nguyen, Austin
    Thornton, Christina S.
    Waddell, Barbara
    Williamson, Tyler
    Rabin, Harvey R.
    Parkins, Michael D.
    BMC INFECTIOUS DISEASES, 2017, 17
  • [27] Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to Streptococcus pseudopneumoniae
    Alvarado, Maria
    Mart-N-Galiano, Antonio J.
    Ferrandiz, Maria J.
    Zaballos, Angel
    de la Campa, Adela G.
    FRONTIERS IN MICROBIOLOGY, 2017, 8
  • [28] Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor
    Singh, Sachinkumar B.
    McLearn-Montz, Amanda J.
    Milavetz, Francesca
    Gates, Levi K.
    Fox, Christopher
    Murry, Logan T.
    Sabus, Ashley
    Porterfield, Harry S.
    Fischer, Anthony J.
    PEDIATRIC PULMONOLOGY, 2019, 54 (08) : 1200 - 1208
  • [29] Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?
    Kate Skolnik
    Austin Nguyen
    Christina S. Thornton
    Barbara Waddell
    Tyler Williamson
    Harvey R. Rabin
    Michael D. Parkins
    BMC Infectious Diseases, 17
  • [30] Use of genomics to design a diagnostic assay to discriminate between Streptococcus pneumoniae and Streptococcus pseudopneumoniae
    Croxen, Matthew A.
    Lee, Tracy D.
    Azana, Robert
    Hoang, Linda M.
    MICROBIAL GENOMICS, 2018, 4 (07):